Floatz logo

Fludarabine

Myelodysplastic Syndrome With Ring Sideroblasts

Explore 2 assets in Myelodysplastic Syndrome With Ring Sideroblasts →
Floatz Rating
BB71/100
Confidence
Indicative
v0.2
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT02566304CT.gov
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
—Completed———
NCT01384513CT.gov
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
—Completed———
NCT00002798CT.gov
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Myelodysplastic Syndrome With Ring Sideroblasts

AssetSponsorPhaseRating
Fludarabine (this asset)Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityP3BB · 71
Cyclosporin ANational Cancer Institute (NCI)P2BB
NivestimNational Cancer Institute (NCI)P3BB
CyclophosphamideSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityP3BB
TacrolimusSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityP2BB
DexasoneNational Cancer Institute (NCI)P3BB
BusulfanumSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityP3BB
DaunomycinNational Cancer Institute (NCI)P3BB
SargramostimNational Cancer Institute (NCI)P2BB

+13 more in the Myelodysplastic Syndrome With Ring Sideroblasts cohort

Other indications for Fludarabine

IndicationSponsorPhaseRating
Adult T-Cell Leukemia/Lymphoma—P2BBB · 76
Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22)—P2BBB · 76
Fanconi Anemia—P2/3BBB · 76

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Fludarabine in Myelodysplastic Syndrome With Ring Sideroblasts. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/fludarabine-myelodysplastic-syndrome-with-ring-sideroblasts-8469

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →